Quoin Pharmaceuticals

QNRX

Market cap $11.7M

Confirmation Received from MHLW That QRX003 Qualifies for Both Orphan Drug Designation and Fast Track Regulatory Review Status

QRX003 could become the first ever approved treatment for Netherton Syndrome ASHBURN, Va., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd.

– Private Placement Financing of Up to $105.3 Million Closed in October 2025 to Fund Operations and R&D – Sally Lawlor Appointed CFO to Support Commercialization and Financial Operations – Orphan Drug Designation Awarded by FDA to QRX003 for Netherton Syndrome  – Pediatric Netherton Clinical Program Expanded Based on Positive Long-Term Safety and Efficacy Data – QRX003 Pivotal Studies to Commence Enrollment in Q4 2025 – NETHERTON NOW Awareness Campaign Videos Achieve Over 1.5 Million Views in 6 Months Since Launch. – Positive Peeling Skin Data and Study Expansion Plans Released ASHBURN, Va.

ASHBURN, Va., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Company" or "Quoin"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that it plans to provide an operational update highlighting key achievements from the quarter, recent accomplishments, and financial highlights for the third quarter ended September 30, 2025, before the market opens on Thursday, November 6, 2025.

U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling around 2.5% on Friday.

PIPE financing included participation from leading healthcare-focused institutional investors including AIGH Capital Management, Soleus Capital, Nantahala Capital, Diadema Partners, Stonepine Capital Management, ADAR1 Capital Management, and Velan Capital, among others PIPE financing included participation from leading healthcare-focused institutional investors including AIGH Capital Management, Soleus Capital, Nantahala Capital, Diadema Partners, Stonepine Capital Management, ADAR1 Capital Management, and Velan Capital, among others

New Episode Highlights the Social and Emotional Impact of Netherton Syndrome, the Importance of Supportive Communities, and the Urgent Need for an Approved Treatment New Episode Highlights the Social and Emotional Impact of Netherton Syndrome, the Importance of Supportive Communities, and the Urgent Need for an Approved Treatment

ASHBURN, Va., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical stage specialty pharmaceutical company focused on rare and orphan diseases, today announced the appointment of its new Chief Financial Officer as the Company advances its lead product candidate, QRX003, through pivotal clinical studies and prepares for potential commercialization.

New Episode Highlights the Painful, Often Misunderstood Reality of Living with Netherton Syndrome and the Urgent Need for Effective Treatments New Episode Highlights the Painful, Often Misunderstood Reality of Living with Netherton Syndrome and the Urgent Need for Effective Treatments

Quoin (QNRX) Q2 Loss Beats Estimates